Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major Europe...(rals and isthe fourth most common cause ...)

"Having followed the development of MammaPrint and CupPrint, we are excited about the opportunity for Ferrer inCode to expand the commercialization of these gene expression profiling tools in these four European countries," said Dr. Carlos de Lecea, vice president, International and Business Development at Ferrer. "Both tests provide valuable information that can be used to guide the therapeutic decision making process of oncologists, opening the door to a more personalized treatment for cancer patients."

The companies are also discussing the possibility of future cooperation and expansion into other parts of the world.

About Ferrer inCode and Grupo Ferrer Internacional

Ferrer inCode is the biotech subsidiary of Grupo Ferrer Internacional, working specifically in the field of personalized medicine as a provider of diagnostic orientation, prognosis and prediction services based chiefly on genomics, proteomics, metabolomics and bioinformatics. The vision of Ferrer inCode is to help doctors make the most accurate clinical decisions for every patient through advanced biotechnological services. Grupo Ferrer Internacional is a privately held European R&D-based pharmaco-chemical and medical device company headquartered in Barcelona, Spain. Ferrer operates today in over 60 countries with the overall aim of improving people's health and quality of life. Based on its policy of continuous expansion throughout the world, Ferrer has established strong industrial and commercial operations in Europe and has extensive commercial experience in Latin America, Africa, the Middle East and Far East. For more information on Ferrer, visit http://www.ferrergrupo.com or http://www.ferrerincode.com.

About Agendia

Agendia, located in Amsterdam, The Netherlands, is a world
'/>"/>